CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 38 enrolled
Drug / intervention
Transcatheter Aortic Valve Implantation (TAVI)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02903420
NCT02903420N/AActive

A Clinical Trial for Transcatheter Aortic Valve Implantation in Chronic Dialysis Patients With Aortic Valve Stenosis

Edwards Lifesciences·interventional·Posted Sep 16, 2016·Updated Sep 25, 2024

In Brief

A clinical study evaluating Transcatheter Aortic Valve Implantation (TAVI) for Aortic Stenosis. Active but no longer recruiting, targeting 38 participants across 2 sites.

Detailed Summary

A single arm, prospective, open, non-randomized, Japanese multicenter trial to evaluate the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve System (Model: 9600TFX) in the treatment of symptomatic severe aortic stenosis patients on chronic dialysis, who are determined by the heart team to be unable to undergo safe open surgical therapy and have the benefits of the study valve implantation. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Stenosis
CountriesJapan
Collaborators--

Timeline

N/AActiveOverdue
2017201820192020202120222023202420252026
First PostedSep 16, 2016
Enrollment StartSep 1, 2016
Primary CompletionFeb 14, 2019
Study CompletionJan 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.8 years ago

Interventions

Transcatheter Aortic Valve Implantation (TAVI)device

Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.